Literature DB >> 7786770

Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia.

N Sadamori1, M Ichiba, M Mine, S Hakariya, T Hayashibara, T Itoyama, H Nakamura, M Tomonaga, K Hayashi.   

Abstract

To clarify the clinical and biological significance of serum thymidine kinase (TK) in adult T-cell leukaemia (ATL) associated with human lymphotropic virus type-I (HTLV-I) and in acute myeloid leukaemia (AML), TK was measured in 52 patients with ATL (acute ATL, 35 patients; lymphoma ATL, two patients; chronic ATL, 12 patients; smouldering ATL, three patients), and in 27 patients with AML (one FAB MO, one M1, 10 M2, seven M3, five M4, one M5, one M6, one MU). In ATL patients, statistical analysis disclosed a close correlation between TK level and the leucocyte count (P < 0.01), and absolute number of abnormal lymphocytes (P < 0.01). However, no correlation was observed between serum lactic dehydrogenase (LDH) level and these items. Concerning the therapeutic response, a statistical difference was present in TK between complete remission and no response (P < 0.05), but not in LDH. We also investigated a significant inverse correlation between TK level as well as LDH level and the length of survival after the initial diagnosis (P < 0.01). In AML patients a close correlation of TK level with the count of leucocytes (P < 0.01), percentage of blasts in the blood (P < 0.05), therapeutic response (P < 0.01) and the length of survival after the initial diagnosis (P < 0.05) was present. Therefore the TK level may indicate the aggressiveness of leukaemic cells and predict the response to the chemotherapy and the length of survival in ATL and AML.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786770     DOI: 10.1111/j.1365-2141.1995.tb03386.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Int J Cancer Oncol       Date:  2015-06-02

2.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

3.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

Review 4.  Current status of therapeutic approaches to adult T-cell leukemia.

Authors:  Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.319

5.  Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.

Authors:  K A Selting; R Ringold; B Husbands; P O Pithua
Journal:  J Vet Intern Med       Date:  2016-05-23       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.